MA42701B1 - Compositions d'insuline à action rapide - Google Patents

Compositions d'insuline à action rapide

Info

Publication number
MA42701B1
MA42701B1 MA42701A MA42701A MA42701B1 MA 42701 B1 MA42701 B1 MA 42701B1 MA 42701 A MA42701 A MA 42701A MA 42701 A MA42701 A MA 42701A MA 42701 B1 MA42701 B1 MA 42701B1
Authority
MA
Morocco
Prior art keywords
acting insulin
rapid acting
insulin compositions
insulin
analogue
Prior art date
Application number
MA42701A
Other languages
English (en)
Other versions
MA42701A (fr
Inventor
Michael Patrick Akers
Ranajoy Majumdar
Chi A Nguyen
Chad D Paavola
Virender Kumar Sarin
Nanette Elizabeth Schulte
Michael Edward Christe
Thomas Andrew Hardy
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57003563&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA42701(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA42701A publication Critical patent/MA42701A/fr
Publication of MA42701B1 publication Critical patent/MA42701B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne une composition pharmaceutique d'insuline humaine ou d'analogue d'insuline, qui comprend du citrate, du tréprostinil et des agents de stabilisation, qui a une action pharmacocinétique et/ou pharmacodynamique plus rapide que des formulations commerciales de produits analogues d'insuline existants, et qui est stable pour une utilisation commerciale.
MA42701A 2015-08-27 2016-08-19 Compositions d'insuline à action rapide MA42701B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562210469P 2015-08-27 2015-08-27
PCT/US2016/047723 WO2017034956A1 (fr) 2015-08-27 2016-08-19 Compositions d'insuline à action rapide

Publications (2)

Publication Number Publication Date
MA42701A MA42701A (fr) 2018-07-04
MA42701B1 true MA42701B1 (fr) 2023-01-31

Family

ID=57003563

Family Applications (1)

Application Number Title Priority Date Filing Date
MA42701A MA42701B1 (fr) 2015-08-27 2016-08-19 Compositions d'insuline à action rapide

Country Status (39)

Country Link
US (3) US9901623B2 (fr)
EP (2) EP4169505A1 (fr)
JP (2) JP6359780B2 (fr)
KR (1) KR102018998B1 (fr)
CN (1) CN107920992B (fr)
AR (2) AR105712A1 (fr)
AU (1) AU2016310475B2 (fr)
BR (1) BR112018001755A2 (fr)
CA (1) CA2994427C (fr)
CL (1) CL2018000503A1 (fr)
CO (1) CO2018002026A2 (fr)
CR (1) CR20180118A (fr)
DK (1) DK3340966T3 (fr)
DO (1) DOP2018000059A (fr)
EA (1) EA033396B1 (fr)
EC (1) ECSP18014922A (fr)
ES (1) ES2928664T3 (fr)
FI (1) FI3340966T3 (fr)
HR (1) HRP20221367T1 (fr)
HU (1) HUE060626T2 (fr)
IL (1) IL256939B (fr)
JO (1) JO3749B1 (fr)
LT (1) LT3340966T (fr)
MA (1) MA42701B1 (fr)
MD (1) MD3340966T2 (fr)
MX (1) MX379267B (fr)
MY (1) MY195781A (fr)
NZ (1) NZ739338A (fr)
PE (1) PE20180782A1 (fr)
PH (1) PH12018500422B1 (fr)
PL (1) PL3340966T3 (fr)
PT (1) PT3340966T (fr)
RS (1) RS63731B1 (fr)
SV (1) SV2018005643A (fr)
TN (1) TN2018000056A1 (fr)
TW (1) TWI614025B (fr)
UA (1) UA120142C2 (fr)
WO (1) WO2017034956A1 (fr)
ZA (1) ZA201800511B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150082640A (ko) 2012-11-13 2015-07-15 아도시아 치환된 음이온성 화합물을 포함하는 속효성 인슐린 제형
TW201630622A (zh) * 2014-12-16 2016-09-01 美國禮來大藥廠 速效胰島素組合物
JO3749B1 (ar) * 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول
GB201607918D0 (en) 2016-05-06 2016-06-22 Arecor Ltd Novel formulations
AU2017334290B2 (en) 2016-09-29 2023-04-20 Arecor Limited Novel formulations
WO2018222787A1 (fr) * 2017-06-01 2018-12-06 Eli Lilly And Company Compositions d'insuline à action rapide
US11510967B2 (en) 2017-09-08 2022-11-29 Eli Lilly And Company Pharmaceutical combinations comprising insulin and at least an agent selected from meloxicam, bromfenac sodium, acetylsalicylic acid, salicyclic acid and paracetamol
US20210113763A1 (en) * 2018-04-04 2021-04-22 Arecor Limited Medical infusion pump system for the delivery of an insulin compound
WO2019193349A1 (fr) * 2018-04-04 2019-10-10 Arecor Limited Système de pompe à perfusion médicale pour l'administration d'un composé d'insuline
IL277721B2 (en) * 2018-04-04 2024-03-01 Arecor Ltd Medical infusion pump system for the delivery of an insulin compound
FR3083985A1 (fr) 2018-07-23 2020-01-24 Adocia Dispositif pour injecter une solution d'insuline(s)
FR3083984A1 (fr) 2018-07-23 2020-01-24 Adocia Dispositif pour injecter une solution d'insuline(s)
WO2019243627A1 (fr) 2018-06-23 2019-12-26 Adocia Dispositif pour injecter une solution d'insuline(s)
US12102610B2 (en) * 2018-09-18 2024-10-01 Eli Lilly And Company Treprostinil salt
CN114096269B (zh) * 2019-07-12 2024-06-11 诺和诺德股份有限公司 高浓度胰岛素制剂
TW202214292A (zh) * 2020-06-30 2022-04-16 大陸商江蘇恆瑞醫藥股份有限公司 速效胰島素組成物及其醫藥用途

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2740953A1 (de) 1977-09-12 1979-03-22 Thera Ges Fuer Patente Verwendung von prostaglandinen zur senkung des blutzuckerspiegels
DE3064888D1 (en) 1979-04-30 1983-10-27 Hoechst Ag Aqueous solutions of proteins stable against denaturization, process for their manufacture, and their utilization
ZA821243B (en) * 1981-03-10 1983-01-26 Novo Industri As Stabilized insulin preparation and method for their production
FI78616C (fi) 1982-02-05 1989-09-11 Novo Industri As Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt.
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
DK503386D0 (da) * 1986-10-20 1986-10-20 Novo Industri As Peptidpraeparater
WO1988006599A1 (fr) 1987-02-25 1988-09-07 Novo Industri A/S Nouveaux derives d'insuline
US5716927A (en) 1988-12-23 1998-02-10 Novo Nordisk A/S Insulin analogs having a modified B-chain
HUT56857A (en) 1988-12-23 1991-10-28 Novo Nordisk As Human insulin analogues
US5474978A (en) 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
JPH11292787A (ja) * 1995-08-15 1999-10-26 Asahi Chem Ind Co Ltd 生理活性ペプチドを含有する経粘膜投与製剤
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
US5866538A (en) 1996-06-20 1999-02-02 Novo Nordisk A/S Insulin preparations containing NaCl
AUPO066096A0 (en) 1996-06-26 1996-07-18 Peptide Delivery Systems Pty Ltd Oral delivery of peptides
JPH10251146A (ja) 1997-03-11 1998-09-22 Toray Ind Inc 糖尿病性神経障害の治療方法
EP1044016B1 (fr) 1998-01-09 2005-03-16 Novo Nordisk A/S Compositions d'insuline stabilisees
ES2180511T3 (es) 1999-01-26 2003-02-16 Lilly Co Eli Formulaciones monodispersas de analogos de insulina acilados hexamericos.
JP2003514014A (ja) 1999-11-15 2003-04-15 ティー ガンガル，ハナマラディ 静脈注入のためのブドウ糖およびインスリン含有液体配合物
US20020141946A1 (en) 2000-12-29 2002-10-03 Advanced Inhalation Research, Inc. Particles for inhalation having rapid release properties
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
ATE496064T1 (de) 2002-05-07 2011-02-15 Novo Nordisk As Lösliche formulierungen, die monomeres insulin und acyliertes insulin enthalten
DE10227232A1 (de) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
US20050043391A1 (en) * 2003-07-17 2005-02-24 Fong Benson M. Combination therapies for treatment of hypertension and complications in patients with diabetes or metabolic syndrome
DE602004028155D1 (de) * 2003-12-16 2010-08-26 United Therapeutics Corp Verwendung von treprostinil zur behandlung von ischämischen läsionen
EP2106790B1 (fr) 2004-03-12 2012-10-24 Biodel, Inc. Compositions d'alimentation de médicament à action rapide
US20080090753A1 (en) 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
CN101287457B (zh) 2004-04-12 2011-11-16 联合治疗公司 Treprostinil用于治疗神经性糖尿病的足部溃疡的用途
EP2256130B1 (fr) * 2005-02-02 2013-09-25 Novo Nordisk A/S Nouveaux dérivés d'insuline
JP5410020B2 (ja) * 2005-02-02 2014-02-05 ノヴォ ノルディスク アー／エス インスリン誘導体
WO2007041481A1 (fr) 2005-09-29 2007-04-12 Biodel, Inc. Preparations d'insuline a action rapide et prolongee
US8084420B2 (en) 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
EP1931805A2 (fr) * 2005-09-30 2008-06-18 Perlegen Sciences, Inc. Troubles de la regulation de la glycemie :methodes et depistage et traitement
DE102006047538A1 (de) * 2006-10-07 2008-04-10 Sanofi-Aventis Deutschland Gmbh Medikamentendosiersystem mittels Mikropumpe
DE102006047613A1 (de) * 2006-10-07 2008-04-10 Sanofi-Aventis Deutschland Gmbh Peristaltische Mikropumpe mit wechselbarem Pumpenkopf
WO2008152106A1 (fr) 2007-06-13 2008-12-18 Novo Nordisk A/S Formulation pharmaceutique contenant un dérivé d'insuline
EP2190433A2 (fr) * 2007-08-22 2010-06-02 Gilead Colorado, Inc. Thérapie pour complications du diabète
TWI394580B (zh) 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
TWI451876B (zh) * 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
US9387033B2 (en) 2008-08-28 2016-07-12 Roche Diabetes Care, Inc. Device and method for enhanced subcutaneous insulin absorption
US9060927B2 (en) 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
US20120094902A1 (en) 2009-03-27 2012-04-19 Adocia Fast-acting insulin formulation
FR2943538B1 (fr) 2009-03-27 2011-05-20 Adocia Formulation a action rapide d'insuline recombinante humaine
KR101775000B1 (ko) 2009-06-26 2017-09-04 노보 노르디스크 에이/에스 인슐린, 니코틴아미드 및 아미노산을 포함하는 제제
BR112012011237A2 (pt) 2009-11-13 2019-09-24 Univ Tokyo agente terapêutico e profilático para diabetes
US20120178675A1 (en) 2010-07-07 2012-07-12 Biodel Inc. Compositions And Methods For Modulating The Pharmacokinetics and Pharmacodynamics of Insulin
CN103328006A (zh) 2010-12-14 2013-09-25 诺沃—诺迪斯克有限公司 包含胰岛素、烟酰胺和氨基酸的制剂
BR112013032265A2 (pt) 2011-06-17 2016-12-20 Halozyme Inc métodos de infusão de insulina subcutânea contínua com uma enzima de degradação do hialuronano
US20130011378A1 (en) 2011-06-17 2013-01-10 Tzung-Horng Yang Stable formulations of a hyaluronan-degrading enzyme
US20130231281A1 (en) 2011-11-02 2013-09-05 Adocia Rapid acting insulin formulation comprising an oligosaccharide
JP5912426B2 (ja) * 2011-11-07 2016-04-27 ヤマハ発動機株式会社 リニアコンベア
BR112014016195A2 (pt) 2011-12-30 2020-10-27 Halozyme, Inc. variantes de polipeptídio ph20, formulações e usos das mesmas
US9381247B2 (en) * 2012-04-16 2016-07-05 Biodel Inc. Magnesium compositions for modulating the pharmacokinetics and pharmacodynamics of insulin and insulin analogs, and injection site pain
US9399065B2 (en) 2012-04-16 2016-07-26 Biodel Inc. Magnesium compositions for modulating the pharmacokinetics and injection site pain of insulin
US20150174209A1 (en) 2012-05-25 2015-06-25 Amylin Pharmaceuticals. Llc Insulin-pramlintide compositions and methods for making and using them
US20150065423A1 (en) * 2013-08-30 2015-03-05 Perosphere, Inc. Rapid acting injectable formulations
WO2015106269A2 (fr) 2014-01-13 2015-07-16 Thermalin Diabetes, Llc Formulations d'insuline à action rapide et systèmes d'administration pharmaceutique
WO2015120457A1 (fr) * 2014-02-10 2015-08-13 Biodel Inc. Formulations d'insuline à action ultrarapide stabilisées
JO3624B1 (ar) * 2014-05-08 2020-08-27 Lilly Co Eli تركيبات إنسولين سريعة المفعول
TW201630622A (zh) 2014-12-16 2016-09-01 美國禮來大藥廠 速效胰島素組合物
ES2972423T3 (es) 2015-07-28 2024-06-12 Lilly Co Eli Preparado farmacéutico para mejorar la absorción y la acción hipoglucemiante postprandial de la insulina
JO3749B1 (ar) * 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول

Also Published As

Publication number Publication date
CL2018000503A1 (es) 2018-08-03
EA033396B1 (ru) 2019-10-31
IL256939A (en) 2018-03-29
ES2928664T3 (es) 2022-11-21
PE20180782A1 (es) 2018-05-07
MX379267B (es) 2025-03-11
KR102018998B1 (ko) 2019-09-05
US10925931B2 (en) 2021-02-23
US9901623B2 (en) 2018-02-27
EP4169505A1 (fr) 2023-04-26
RS63731B1 (sr) 2022-12-30
CN107920992A (zh) 2018-04-17
MD3340966T2 (ro) 2023-04-30
LT3340966T (lt) 2022-11-25
EP3340966A1 (fr) 2018-07-04
JP6359780B2 (ja) 2018-07-18
AR105712A1 (es) 2017-11-01
PL3340966T3 (pl) 2023-01-30
SV2018005643A (es) 2018-10-09
PH12018500422B1 (en) 2022-04-01
IL256939B (en) 2019-10-31
ECSP18014922A (es) 2018-04-30
PH12018500422A1 (en) 2018-08-29
UA120142C2 (uk) 2019-10-10
CA2994427A1 (fr) 2017-03-02
US20210169988A1 (en) 2021-06-10
HRP20221367T1 (hr) 2023-01-06
DOP2018000059A (es) 2018-04-15
FI3340966T3 (fi) 2023-01-13
JP2018507869A (ja) 2018-03-22
US20180140676A1 (en) 2018-05-24
ZA201800511B (en) 2019-07-31
AU2016310475B2 (en) 2018-10-18
AR134413A2 (es) 2026-01-14
EP3340966B1 (fr) 2022-10-12
US20170056478A1 (en) 2017-03-02
BR112018001755A2 (pt) 2018-09-18
KR20180033276A (ko) 2018-04-02
EA201890343A1 (ru) 2018-07-31
JP2018172404A (ja) 2018-11-08
MX2018002482A (es) 2018-06-15
TW201717997A (zh) 2017-06-01
CA2994427C (fr) 2019-07-09
JO3749B1 (ar) 2021-01-31
PT3340966T (pt) 2022-12-05
AU2016310475A1 (en) 2018-02-15
HUE060626T2 (hu) 2023-03-28
CR20180118A (es) 2018-03-20
NZ739338A (en) 2019-06-28
TN2018000056A1 (en) 2019-07-08
TWI614025B (zh) 2018-02-11
WO2017034956A1 (fr) 2017-03-02
JP6935364B2 (ja) 2021-09-15
MA42701A (fr) 2018-07-04
MY195781A (en) 2023-02-13
DK3340966T3 (da) 2022-10-24
CO2018002026A2 (es) 2018-05-21
CN107920992B (zh) 2021-06-18

Similar Documents

Publication Publication Date Title
MA42701B1 (fr) Compositions d'insuline à action rapide
MA41188B1 (fr) Compositions d'insuline à action rapide
MA39441A1 (fr) Composition d'insuline a action rapide
MA42678B1 (fr) Nouveaux analogues nucléosidiques substitués à cycle aromatique bicyclique 6-6 pour une utilisation en tant qu'inhibiteurs de prmt5
PH12018501502A1 (en) Egf(a) analogues with fatty acid substituents
MA39726A (fr) Compositions pharmaceutiques de composés thérapeutiquement actifs
MA56049A (fr) Formulations stabilisées contenant des anticorps anti-angptl3
MA52309B1 (fr) Régulateurs de nrf2
SA521421715B1 (ar) تركيبات سيماجلوتيد ثابتة واستخداماتها
MA39725B1 (fr) Compositions pharmaceutiques de composés thérapeutiquement actifs
MX2019004580A (es) Formulaciones farmaceuticas y metodos para prepararlas.
EP3773900A4 (fr) Analogues d'hinokitiol, procédés de préparation et compositions pharmaceutiques de ceux-ci
MA38646A1 (fr) Formulation a liberation modifiee pour traiter, par ex. La maladie de parkinson et la dyskinesie induite par l-dopa.
MA55362A (fr) Formulations stabilisées contenant des anticorps anti-il-33
MY190102A (en) Tolerogenic dna vaccine
PH12020551618A1 (en) Erenumab compositions and uses thereof
EP3399040A4 (fr) Procédé de préparation d'une protéine de capside de circovirus porcin de type 2 et composition pharmaceutique la contenant
MA39272A (fr) Formulations à libération prolongée de gabapentine
BR112022023738A2 (pt) Formulação líquida
MA55298A (fr) Compositions pharmaceutiques contenant des anticorps anti-lingo-1
TH1801001060A (th) องค์ประกอบอินซูลินชนิดออกฤทธิ์รวดเร็ว
TH168567A (th) องค์ประกอบอินซูลินออกฤทธิ์รวดเร็ว
TH170460A (th) องค์ประกอบเภสัชภัณฑ์สำหรับการให้ทางปากซึ่งประกอบรวมด้วยแทกเซน
TN2014000127A1 (fr) Composition pharmaceutique effervescente a desagregation rapide a base de prednisolone metasulfobenzoate et son procede de fabrication
MA34795B1 (fr) Composition pharmaceutique solide pour administration buccale d'agomelatine